Literature DB >> 15265880

Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells.

Theresa L Whiteside1, Joanna Stanson, Michael R Shurin, Soldano Ferrone.   

Abstract

It has been known for some time that functional properties of dendritic cells (DC), and in particular their ability to process and present Ags to T cells, can be modulated by cytokine-induced maturation and by interactions with tumor cells. However, the molecular basis for these functional changes is unknown. We have investigated whether changes in expression of Ag-processing machinery (APM) components in DC are associated with alterations in their ability to present tumor-derived Ags to T cells. Using a panel of mAbs specific for individual APM components and a quantitative flow cytometry-based method, the level of APM components was measured in DC generated from peripheral blood monocytes of 12 normal donors and of 8 patients with cancer. Immature DC had significantly lower (p < 0.01) expression of MB1, LMP-7, LMP-10, TAP-1, and tapasin than mature DC. However, maturation in the presence of a cytokine mixture up-regulated expression of these components in DC obtained from normal donors and patients with cancer. Immature DC incubated with tumor cells had significantly lower (p < 0.001) expression of MB1, LMP-2, LMP-7, LMP-10, and endoplasmic reticulum p75 than controls. These changes were associated with a decreased ability of DC to present tumor-derived Ags to T cells, as measured in ELISPOT assays and with apoptosis of T cells in DC-T cell cultures. Thus, tumor cells have a significant suppressive effect on DC; however, ex vivo maturation of DC derived from patients with cancer in a polarizing cytokine mix restores normal expression of APM components and Ag-processing capabilities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15265880     DOI: 10.4049/jimmunol.173.3.1526

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

Review 1.  The specialized roles of immature and mature dendritic cells in antigen cross-presentation.

Authors:  Richard A Hopkins; John E Connolly
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

2.  Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells.

Authors:  Sabrina Chiesa; Silvia Morbelli; Sara Morando; Michela Massollo; Cecilia Marini; Arinna Bertoni; Francesco Frassoni; Soraya Tabera Bartolomé; Gianmario Sambuceti; Elisabetta Traggiai; Antonio Uccelli
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-29       Impact factor: 11.205

Review 3.  Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.

Authors:  Theresa L Whiteside
Journal:  Expert Opin Biol Ther       Date:  2010-07       Impact factor: 4.388

Review 4.  Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy.

Authors:  Carsten Denkert; Silvia Darb-Esfahani; Sibylle Loibl; Ioannis Anagnostopoulos; Korinna Jöhrens
Journal:  Semin Immunopathol       Date:  2011-04-17       Impact factor: 9.623

5.  Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma.

Authors:  Vito Racanelli; Patrizia Leone; Maria Antonia Frassanito; Claudia Brunetti; Federico Perosa; Soldano Ferrone; Franco Dammacco
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

6.  Human mesothelioma induces defects in dendritic cell numbers and antigen-processing function which predict survival outcomes.

Authors:  Scott M J Cornwall; Matthew Wikstrom; Arthur W Musk; John Alvarez; Anna K Nowak; Delia J Nelson
Journal:  Oncoimmunology       Date:  2015-08-31       Impact factor: 8.110

7.  [Immunotherapy of head and neck cancer. Current developments].

Authors:  P J Schuler; T K Hoffmann; T C Gauler; C Bergmann; S Brandau; S Lang
Journal:  HNO       Date:  2013-07       Impact factor: 1.284

8.  Phase I dendritic cell p53 peptide vaccine for head and neck cancer.

Authors:  Patrick J Schuler; Malgorzata Harasymczuk; Carmen Visus; Albert Deleo; Sumita Trivedi; Yu Lei; Athanassios Argiris; William Gooding; Lisa H Butterfield; Theresa L Whiteside; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

9.  Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism.

Authors:  Galina V Shurin; Irina L Tourkova; Ramon Kaneno; Michael R Shurin
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

10.  Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus.

Authors:  Lazar Vujanovic; Theresa L Whiteside; Douglas M Potter; Jessica Chu; Soldano Ferrone; Lisa H Butterfield
Journal:  Cancer Immunol Immunother       Date:  2008-05-17       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.